Zealand Pharma A/S
General ticker "ZLDPF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.1B (TTM average)
Zealand Pharma A/S follows the US Stock Market performance with the rate: 7.1%.
Estimated limits based on current volatility of 0.7%: low 67.50$, high 68.43$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [61.96$, 123.71$]
- 2025-12-31 to 2026-12-31 estimated range: [49.61$, 103.28$]
Financial Metrics affecting the ZLDPF estimates:
- Negative: with PPE of -43.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.91 <= 0
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.07 <= 0.73
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -15.08 <= -14.20
- Positive: Shareholder equity ratio, % of 90.65 > 64.37
Short-term ZLDPF quotes
Long-term ZLDPF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | DKK103.99MM | DKK342.79MM | DKK62.69MM |
| Operating Expenses | DKK920.59MM | DKK915.03MM | DKK1,334.90MM |
| Operating Income | DKK-816.60MM | DKK-572.24MM | DKK-1,272.21MM |
| Non-Operating Income | DKK-155.44MM | DKK-136.63MM | DKK188.76MM |
| Interest Expense | DKK56.45MM | DKK24.89MM | DKK34.05MM |
| R&D Expense | DKK614.04MM | DKK684.90MM | DKK919.87MM |
| Income(Loss) | DKK-972.04MM | DKK-708.87MM | DKK-1,083.44MM |
| Taxes | DKK-6.43MM | DKK-5.13MM | DKK-4.62MM |
| Profit(Loss)* | DKK-729.09MM | DKK-703.74MM | DKK-1,078.83MM |
| Stockholders Equity | DKK815.91MM | DKK1,592.84MM | DKK8,616.74MM |
| Inventory | DKK1.29MM | DKK7.93MM | DKK10.70MM |
| Assets | DKK1,539.81MM | DKK1,979.99MM | DKK9,505.60MM |
| Operating Cash Flow | DKK-942.21MM | DKK-425.67MM | DKK-930.82MM |
| Capital expenditure | DKK11.71MM | DKK23.75MM | DKK13.15MM |
| Investing Cash Flow | DKK281.26MM | DKK-1,094.03MM | DKK-7,332.91MM |
| Financing Cash Flow | DKK587.40MM | DKK907.01MM | DKK8,288.49MM |
| Earnings Per Share** | DKK-15.78 | DKK-12.44 | DKK-16.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.